Elisabetta Poluzzi

TL;DR: A pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K(+) channel blockers, and a theoretical screening tool able to predict whether a new molecule can interact with the HERG channel and eventually induce the long QT syndrome.

TL;DR: Insight is provided into the strategies that should be followed during a drug development program when a drug is suspected to affect the QT interval and the factors limiting the predictive value of preclinical and clinical studies are outlined.

TL;DR: The mechanisms leading to QT prolongation are outlined and the different strategies that can be followed to predict this unwanted effect are outlined, and the approaches recently proposed for the in silico screening of new compounds are focused on.

TL;DR: It has been suggested that the serotonergic (5‐HT4) component of some antidopaminergic prokinetics may enhance their therapeutic efficacy in gastrointestinal disorders, such as functional dyspepsia and diabetic gastroparesis.

TL;DR: This review provides an update on the different classes of non-cardiac drugs reported to prolong the QT interval, on the possible underlying molecular mechanisms and on the clinical relevance of theQT prolonging effect.